American Journal of Cardiology
Volume 105, Issue 8 , Pages 1153-1158, 15 April 2010

Value of Tissue Doppler Echocardiography in Predicting Response to Cardiac Resynchronization Therapy in Patients With Heart Failure

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Received 21 October 2009; received in revised form 3 December 2009; accepted 3 December 2009. published online 22 February 2010.

Several studies have demonstrated a relation between left ventricular (LV) dyssynchrony and response to cardiac resynchronization therapy (CRT). Many methods of determining LV dyssynchrony have been proposed, including a value of 65 ms as assessed by tissue Doppler imaging. The aim of the present validation study was to prospectively test the predictive accuracy of the 65-ms cutoff for LV dyssynchrony in a large cohort of patients with heart failure undergoing CRT. The study included 361 patients who had undergone CRT. The clinical and echocardiographic parameters were assessed at baseline and at 6 months of follow-up. The clinical response was defined as an improvement of ≥1 New York Heart Association class, and the echocardiographic response was defined as a reduction in LV end-systolic volume of ≥15%. At 6 months of follow-up, 259 patients (72%) had a clinical response and 187 patients (52%) had an echocardiographic response. The patients with a response had more LV dyssynchrony than did those without a response (91 ± 49 ms vs 50 ± 44 ms for the clinical response and 101 ± 46 ms vs 55 ± 45 ms for the echocardiographic response). On multivariate analysis, LV dyssynchrony remained predictive of the response, independent of other characteristics. In conclusion, LV dyssynchrony of ≥65 ms was an independent predictor of both the clinical and the echocardiographic response in patients with heart failure who underwent CRT in this validation study.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Bax received grants from Medtronic, Minneapolis, Minnesota, Biotronik, Lake Oswego, Oregon, Boston Scientific, Natick, Massachusetts, BMS Medical Imaging, North Billerica, Massachusetts, St. Jude Medical, St. Paul, Minnesota, Edwards Life Sciences, Irvine, California, and GE Healthcare, St. Giles, United Kingdom. Dr. Schalij received grants from Biotronik, Lake Oswego, Oregon, Medtronic, Minneapolis, Minnesota, and Boston Scientific, Natick, Massachusetts.

PII: S0002-9149(09)02848-3

doi:10.1016/j.amjcard.2009.12.018

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1153-1158, 15 April 2010